It is known that ARNI therapy that is initiated as early as possible can lead to greater cardiac reverse remodeling benefit in HF patients, having a reduced ejection fraction vs. angiotensin receptor blockers or angiotensin-converting enzyme suppressors. The gene discussed is ACE; the disease is hydrops fetalis.